The Claim
In adult female mice undergoing 8 weeks of progressive weighted wheel running, intermittent rapamycin administration (2 mg/kg, once weekly) leads to greater voluntary running volume compared to frequent rapamycin (2 mg/kg, three times weekly) or vehicle treatment, primarily due to increased running speeds; however, this higher activity level does not result in greater fat loss or improved metabolic outcomes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Female mice on a weekly rapamycin dose ran more and faster than those on a more frequent dose or no drug, but despite running more, they didn’t lose more fat or get healthier metabolically.
See the scientific wording
Adult female mice treated with intermittent rapamycin (2 mg/kg, once weekly) during 8 weeks of progressive weighted wheel running exhibit greater voluntary running volume than those treated with frequent rapamycin (2 mg/kg, three times weekly) or vehicle, primarily due to higher running speeds, though this increased activity does not translate into greater fat loss or improved metabolic outcomes.
What the research says
1 studyStudy: Rapamycin Does Not Compromise Exercise‐Induced Muscular Adaptations in Female Mice
Mice on weekly rapamycin ran more than those on daily doses or no drug, but they didn’t get healthier metabolically—even though they exercised more.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.